Want to Calculate Fair Value?
Enter Stock | Calculate Fair Value

Stock: OGN
Book Value Per Share: $2.101
EPS: $2.00
Diluted EPS TTM: $2.89
Dividend Per Share: 1.12
Dividend Yield: 11.49 %
Dividend Payout Ratio: 56%
Price To Sales Ratio TTM: 0.416
Price To Book Ratio: 4.835
PEG Ratio: None
EV To EBITDA: 7.45
P/E Ratio: 3.488
Forward P/E Ratio: 5.03
Ex Dividend Date: 2025-05-12
Dividend Date: 2025-06-12
Current Price: $9.75
Previous Close: $9.88
52 Week Low: $8.01
52 Week High: $22.24
Earning Date (within 30 days): N/A
50 Day MA: $10.41
200 Day MA: $15.13
Link to Yahoo (Financial): OGN

Advertisement
 
* Note: Prices are in Million (M) USD.
Description:
Organon & Co (OGN) â–¼
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, Hormone replacement therapy (HRT), and anesthesia. The company sells to international markets.
These criteria used Company’s Cash, EBITDA and Debt balance to determines its fair value:
Cash : $675 M
Debt : $8,860 M
EBITDA : $1,695 M
Net Debt (Debt - Cash): $8,185 M

Since EBITDA cannot cover net debt within 3 years, Avoid This Stock.
This criteria used industry in which company operates:
Sector: Healthcare
Industry: Medicinal and Botanical Manufacturing

Based on industry, 3 points assigned.
This criteria used Company’s Price To Earning (P/E) Ratio to determines its fair value:
Forward PE Ratio: 4.88

Since Forward PE Ratio is less than 15, 5 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Average Free Cash Flow: $1,381 M
Average Revenue: $7,662 M
Revenue Converted To Free Cash FLow(%): 18 %
Since Free Cash Flow (FCF) to Revenue percentage is greater than 15, 3 points assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2024-12-31): $6,403 M
Revenue 4 Years Ago (2020-12-31): $8,096 M
Last 5 Years Average Revenue Growth: -4%

Since Revenue Growth is between 0 - 5, 1 point assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2024-12-31): $259 M
Share Count 5 Years Ago (2020-12-31): $254 M

Company is not buying back its own shares, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Earnings Per Share (EPS): $2.00
Dividend Per Share (DPS): $1
Payout Ratio: 56%
Dividend Yield: 1%

Since company Payout Ratio is greater than 50, 1 point assigned.

Since Dividend Yield is less than 1, 0 point assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Average ROE: 88%

Since Average ROE is greater than 20, 5 points assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $10
52-Week Low: $8
Threshold Price (15% Above 52-Week Low): $9

Since Current price is not within 15% threshold, 0 point assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $2,620 M

Since Market Cap is less than 10B, 1 point assigned.
% Exposure to Total Portfolio
Based on the calculated score, we recommend do not exceed 2% exposure of Total Portfolio.
Value-Trade has assigned 19 points to above Organon & Co (OGN) stock.
Twenty Years Avg PE 5, Fair Value PE 12 and Industry Based PE is 15. Based on these three values average assigned is 10.67.
Value-Trades has assined P/E value 10.67. Since current year earning per share is $2.00.
The fair value of Organon & Co (OGN) stock should be (10.67 x $2.00) = $21.34

Share this valuation:


Advertisement

Advertisement

Advertisement